Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, announced it will deliver an oral presentation on its investigational TNX-801 vaccine platform and lead a working group session at the World Vaccine Congress Europe, scheduled for October 19-21, 2026, in Amsterdam, Netherlands. The presentation, set for October 21 at 1:15 p.m. CEST, will focus on the safety and efficacy of TNX-801, a live, attenuated, minimally replicative horsepox virus-based vaccine platform being developed to protect against mpox and other infectious diseases. Tonix will also lead a working group session titled “Vectored Vaccine Platforms: From Design to Improving Efficacy” on October 20 at 11:30 a.m. CEST.
The announcement matters because it positions Tonix at the forefront of vaccine innovation for emerging infectious diseases. Mpox, formerly known as monkeypox, has been declared a public health emergency by the World Health Organization, and current vaccines have limitations in accessibility and durability. TNX-801’s minimally replicative horsepox platform could offer a safer and more effective alternative, potentially addressing gaps in global preparedness. By presenting at a major international congress, Tonix gains visibility among key stakeholders, which could accelerate partnerships, funding, and eventual regulatory approval. For investors, this signals progress in a pipeline that extends beyond the company’s commercial CNS products, such as TONMYA for fibromyalgia, and into high-growth immunology markets.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Its flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), is the first new treatment for fibromyalgia in more than 15 years. The company’s CNS commercial infrastructure supports marketed products, including acute migraine treatments Zembrace SymTouch and Tosymra. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection. These investigational candidates have not been approved for any indication.
The World Vaccine Congress Europe is a premier event that draws researchers, industry leaders, and policymakers. Tonix’s participation underscores its commitment to addressing unmet needs in infectious disease. The working group session on vectored vaccine platforms will allow the company to share insights on design and efficacy improvements, potentially shaping industry standards. For the broader biotech sector, this news highlights the growing importance of next-generation vaccine platforms in combating emerging threats. Investors can find the latest updates on TNXP in the company’s newsroom at https://ibn.fm/TNXP and view the full press release at https://ibn.fm/BHVjU.
BioMedWire, a specialized communications platform focused on biotechnology and life sciences, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform delivers access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. As Tonix advances its vaccine platform, the implications for public health and investor confidence are significant, making this a development worth watching.


